top of page
  • Active, not recruiting

NCT01857115: Phase 1/2: EMN - Study of Wkly Carfilzomib, Cyclophosphamide and Dexamethasone In NDMM

Updated: Sep 25, 2022

wCCyd

EMN

European Myeloma Network


NCT01857115: Phase 1/2: Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd) (wCCyd)

wccyd

Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd) (wCCyd)


This protocol is a phase I/II multicenter study designed to assess the safety and the efficacy of the proposed combinations as up-front treatment in elderly Multiple Myeloma (MM) patients.


Sponsor


Collaborator

Fondazione EMN Italy Onlus

 

ClinicalTrials.gov Identifier: NCT01857115

Official Title: A MULTICENTER, OPEN LABEL STUDY OF WEEKLY CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (wCCyd) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS

First Posted : May 20, 2013

Click here for the details on ClinicalTrials.gov

 


 

Drug: Carfilzomib

Drug: Cyclophosphamide

Drug: Dexamethasone

 

Haematologica;2021

Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies


Haematologica; 2020

Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs

 

Locations

Italy







Commentaires


Posts Archive
bottom of page